Editing XanGo (section)

===U.S. FDA warning===
On September 20, 2006, the United States [[Food and Drug Administration (United States)|Food and Drug Administration]] issued a [[FDA Warning Letter|warning letter]] to Xango LLC International in response to the company's promotion of Xango juice as an aid to treat and/or cure various diseases.<ref>{{cite web |url=https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2006/ucm076067.htm |title=Warning Letter, Xango LLC, Intl |author=Collins BB, District Director|date=20 September 2006 |website=U.S. Food & Drug Administration |publisher=US Food and Drug Administration, Inspections, Compliance, Enforcement, and Criminal Investigations |access-date=15 May 2013 |url-status=dead |archive-url=https://web.archive.org/web/20120302140609/https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2006/ucm076067.htm |archive-date=2 March 2012}}</ref>  The agency's letter warned that Xango juice had not been properly tested for safety and efficacy, and as a proposed new drug, it could not be legally sold in the U.S. without prior approval of the FDA. Xango was warned that it could face enforcement action including seizure and/or injunction of products or suspension of business. Under FDA drug labeling rules, Xango, as manufacturer, is responsible for satisfying scientific criteria to make health claims on its product labels and all marketing materials. As of September 2008, the case remained open.